High-Risk Valve-in-Valve TAVR With Chronic Type B Aortic Dissection Authors: Koushik Kondapi, Elizabeth Evans, Fareed Moses Collado Published: 2026 ABSTRACT AbstractBackgroundTranscatheter aortic valve replacement (TAVR) is a challenge in patients with chronic aortic dissection given risk of intraoperative dissection extension. There are limited prior case reports.Case SummaryA 45-year-old man with a history of repaired type A dissection and aortic valve replacement with residual type B dissection presented in cardiogenic shock due to severe prosthetic valve stenosis. Because of his surgical risk and rapid decompensation, a valve-in-valve TAVR was successfully performed, followed by resolution of cardiogenic shock.DiscussionWe demonstrate a successful valve-in-valve TAVR in a patient with known type B dissection in the setting of hemodynamic deterioration.Take-Home MessagesTAVR is uniquely challenging in patients with type B aortic dissection but is feasible in the acute setting. Femoral access requires special attention to ensure entry into the true lumen.Key words: acute heart failure, aorta, aortic valve, dissection, stenosis, valve repair, valve replacement Take-Home Messages •TAVR is uniquely challenging in patients with type B aortic dissection but is feasible in the acute setting. TAVR is uniquely challenging in patients with type B aortic dissection but is feasible in the acute setting. •Femoral access requires special attention to ensure entry into the true lumen. Femoral access requires special attention to ensure entry into the true lumen. Past Medical History The patient was a 45-year-old man with a history of chronic, nonischemic cardiomyopathy with mild systolic heart failure, splenic artery rupture having undergone embolization, atrial fibrillation on Eliquis (apixaban), renal-limited ANCA (antineutrophil cytoplasmic antibody) vasculitis, cerebrovascular accident with residual right lower extremity weakness, and cocaine use disorder. His past surgical history included a type A aortic dissection, having undergone repair (reimplantation of the coronaries and aortic ascending and hemiarch replacement with 26-mm graft) with aortic valve replacement (27-mm Inspiris pericardial valve, 34-mm Gelweave graft), with residual type B aortic dissection (TBAD). History of Presenting Illness The patient presented to a nearby hospital with several days of progressive shortness of breath, lower extremity edema, and orthopnea despite diuretics. Transthoracic echocardiography (TTE) on arrival showed a left ventricular ejection fraction (LVEF) of 15% (reduced from 45% at 3 months before admission), severe prosthetic aortic stenosis (peak systolic velocity: 4.6 m/s, mean systolic gradient: 55 mm Hg) and elevated right ventricular systolic pressure. Computed tomography (CT) angiography of the abdomen and pelvis re-demonstrated Stanford type A aortic dissection extending from the proximal aortic arch to the level of the left common iliac artery, postsurgical sternotomy changes, a new saccular aneurysm in the superior mesenteric artery and large-volume thrombosis in the false lumen of the mid-to-distal left common iliac artery. CT also demonstrated the patient's TBAD (Figure 1). His hospital course was complicated by discovery of subacute intracranial hemorrhage, not requiring neurosurgical intervention, and acute renal failure. He was maintained on a heparin drip for the left common iliac thrombus. Computed Tomography Images of Type B Aortic Dissection (Arrow) Differential Diagnosis The most likely differential diagnosis for this patient's shock state was severe aortic stenosis. Less likely diagnoses included myocardial infarction, new valvular abnormality, progression of systolic heart failure, or progression of aortic dissection. Investigations On arrival to our institution, the patient was in SCAI (Society for Cardiovascular Angiography and Interventions) stage D shock with worsening renal function and lactic acidosis despite inotropic support. Initial laboratory values were notable for creatinine 1.80 mg/dL (reference: 0.75-1.2 mg/dL, patient's baseline: 0.8-1 mg/dL), liver transaminases within normal limits, lactate 2.4 mmol/L (reference: 0.5-1.7 mmol/L), hemoglobin 11.4 g/dL (reference: 13.5-17.5 g/dL), and platelet count 80 × 109/L (reference: 150-399 × 109/L). Repeat TTE showed an LVEF of 15% to 20% with severe prosthetic aortic valve stenosis (see Table 1). Table 1Aortic Valve VariablesPre-TAVRPost-TAVRPOD 1POD 52Mean systolic gradient, mm Hg55718Peak systolic gradient, mm Hg861130Peak systolic velocity, m/s4.61.742.8Estimated valve area (by LVOT velocity-time integral method), cm20.42.01.4LVOT = left ventricular outflow tract; POD = postoperative day; TAVR = transcatheter aortic valve replacement. Aortic Valve Variables LVOT = left ventricular outflow tract; POD = postoperative day; TAVR = transcatheter aortic valve replacement. Management After discussion among the heart team, consisting of cardiothoracic surgery, interventional cardiology, and advanced heart failure members, the patient was determined to be at too high a risk for open surgical intervention given his prior surgical history, multiple comorbidities, and rapidly deteriorating clinical status. As such, he was planned for emergent valve-in-valve TAVR. During the procedure, a pulmonary artery catheter was placed with initial hemodynamics as shown in Table 2. Left femoral venous access was established for transvenous pacing. Acknowledging the risk of dissection extension at the level of the iliac arteries with femoral access, special attention was given to ensuring entry into the true lumen. Right femoral percutaneous access was attempted, however a hard mass was encountered in the area, thus a surgical cutdown was performed. Pathology of the mass was consistent with benign lymph node. A 26-mm Edwards S3 Resilia valve was deployed under rapid ventricular pacing. Post-TAVR hemodynamics were significantly improved (Table 1). No paravalvular leak was noted. Post-TAVR invasive hemodynamics were also improved (Table 2). The postoperative course was complicated by an infected hematoma of the right groin, with cultures positive for coagulase-negative staphylococcus. He was treated with a 5-day course of intravenous vancomycin after washout and wound vac placement. Table 2Pre-TAVR and Post-TAVR Right Heart PressuresRight Heart PressuresPre-TAVRPost-TAVRCentral venous pressure, mm Hg2010PA systolic pressure, mm Hg5649PA diastolic pressure, mm Hg3526PA mean pressure, mm Hg4435Pre-TAVR pressures were measured during right heart catheterization; post-TAVR pressures were measured after arrival to floor via leave-in pulmonary artery catheter.PA = pulmonary artery; TAVR = transcatheter aortic valve replacement. Pre-TAVR and Post-TAVR Right Heart Pressures Pre-TAVR pressures were measured during right heart catheterization; post-TAVR pressures were measured after arrival to floor via leave-in pulmonary artery catheter. PA = pulmonary artery; TAVR = transcatheter aortic valve replacement. Outcomes and Follow-Up Postprocedurally, the patient was weaned off inotropic support within 24 hours. He had NYHA functional class II symptoms at discharge. TTE at 2 months showed that LVEF had recovered to 55%, with a normally functioning TAVR (Table 1). Discussion Over the past 2 decades, TAVR has become preferred in many patient subgroups as an alternative to surgical aortic valve replacement because of its superior procedure-associated morbidity.1,2 Thus, use of TAVR has naturally expanded to increasingly complex cases and more urgent circumstances at experienced centers. American College of Cardiology/American Heart Association guidelines describe criteria for patients eligible for aortic valve replacement in the setting of aortic stenosis.3 However, how best to apply these guidelines to each patient's unique circumstance in the setting of multiple complex comorbidities is less evident, and TAVR is technically challenging in patients with chronic TBAD given the risk of dissection extension or aortic rupture via mechanical forces exerted during arterial access.4,5 There are a few prior reports of TAVR in patients with known type B aortic dissection using varying access strategies.4,6,7 Gulkarov et al4 described the first known TAVR in a patient with TBAD originating near the left subclavian artery and ending at the left iliac artery. In their case, access was established in the right radial and femoral arteries, and a stable wire was deployed via the right femoral artery into the true lumen of the descending thoracic aorta. Schumer et al6 also described successful TAVR in a patient with a known TBAD using a transfemoral approach, deploying a stiff wire via the right femoral artery into the ascending aorta. Furthermore, Tsuda et al8 successfully performed a transfemoral TAVR using a 20-F introducer sheath to minimize contact with the false lumen. Alternatively, Liang et al7 opted for a carotid approach in an elderly patient with known TBAD and aneurysm, performed successfully without cerebral vascular accident (CVA). Previous studies have demonstrated an increased risk of CVA with carotid arterial access compared to femoral access,9 while other retrospective propensity-matched analyses demonstrated similar rates of CVA with both access routes.10 In our case, transcarotid and axillary access was considered, but femoral access was preferred given the emergent nature of the case, as access is typically able to be established more quickly via femoral cutdown. Furthermore, the luminal diameters of the carotid and axillary arteries were not favorable. CT imaging suggested that entry to the true lumen via the femoral artery was feasible, and true lumen entry was ensured intraprocedurally by advancing the guidewire under fluoroscopy and ensuring that the expected course was taken around the aortic arch and past the aortic valve. This was further confirmed when the guidewire was navigated into the right subclavian artery, which was known to be unaffected by the TBAD from CT imaging. Intravascular ultrasound can also be a valuable tool to ensure true lumen entry, and our catheterization laboratory team had intravascular ultrasound prepared intraprocedurally if further true lumen confirmation was needed. Other novel strategies to ensure entry into the true lumen have been previously described such as “balloon-flossing,”11 whereby an inflated balloon is advanced over the guidewire and resistance during balloon advancement before valve deployment is assessed to ensure entry into the true lumen. Ultimately, various strategies exist for establishing arterial access and must be carefully weighed while taking into account the unique factors of each case for the treatment of future patients. Our case contributes to this existing literature and, when taken together, these cases underscore the challenge of safely establishing access in the presence of TBAD and demonstrates the importance of careful preprocedural planning with CT angiography review to guide intended entry into the true lumen. This case additionally demonstrates effective multidisciplinary care via a heart team. Continued standardization of the heart team approach across institutions will be important as the patient population who may benefit from TAVR becomes more complex. Conclusions Management of severe aortic stenosis in patients with cardiogenic shock is nuanced, requiring an individualized, patient-centered approach with multidisciplinary collaboration. From our experience, valve-in-valve TAVR in the setting of type B dissection via transfemoral approach is feasible with careful attention to ensuring true lumen entry. Visual SummaryTimeline of the CaseTimeEventsDay 1A 45-year-old man presented to a neighboring hospital in NYHA functional class III heart failure. Patient was started on IV diuresis.Day 2Computed tomography angiography of abdomen and pelvis demonstrated a type B aortic dissection from the proximal aortic arch to the level of the left common iliac artery. TTE with newly reduced ejection fraction of 15% and severe bioprosthetic aortic valve stenosis. Planned for transfer to tertiary care center for escalation of care and surgical evaluation.Day 14Transferred to our institution for management of SCAI stage D cardiogenic shock on dobutamine in the setting of severe prosthetic aortic stenosis. Repeat TTE was notable for ejection fraction 15%-20%. Aortic valve area by velocity time integral of 0.4 cm2, peak systolic velocity 4.6 m/s, and mean systolic gradient 55 mm Hg.Day 15Given the patient's ongoing clinical decompensation and high surgical risk, an urgent valve-in-valve TAVR was performed. After TAVR, mean systolic gradient improved to 7 mm Hg, peak systolic velocity improved to 1.79 m/s, and estimated aortic valve area 2.19 cm2.Day 20Taken back to the OR for exploration of right groin swelling. Noted to have large hematoma draining serosanguinous fluid. Hematoma evacuated and wound vac placed.Day 26Discharged home on GDMT, classified as NYHA functional class II heart failure.Day 42At the 2-week outpatient follow-up with cardiology, the patient had NYHA functional class I symptoms and was recovering well from his hospitalization.Day 67Repeat outpatient TTE demonstrated an improved ejection fraction of 55% with a well-functioning prosthetic valve-in-valve TAVR. Estimated aortic valve area by VTI of 1.4 cm2, peak systolic velocity 2.8 m/s, and mean systolic gradient 18 mm Hg.GDMT = guideline-directed medical therapy; IV = intravenous; OR = operating room; SCAI = Society for Cardiovascular Angiography and Interventions; TAVR = transcatheter aortic valve replacement; TTE = transthoracic echocardiography; VTI = velocity time integral. Timeline of the Case GDMT = guideline-directed medical therapy; IV = intravenous; OR = operating room; SCAI = Society for Cardiovascular Angiography and Interventions; TAVR = transcatheter aortic valve replacement; TTE = transthoracic echocardiography; VTI = velocity time integral. Equipment ListTranscatheter Aortic Valve-in-Valve RepairImaging•Transthoracic echocardiography: Philips Epiq 7 (Philips Healthcare)•Chest/Abdomen/Pelvis computed tomography angiography (external imaging, unknown machine type)•Transesophageal echocardiography: Philips Epiq 7 (Philips Healthcare)Access•Ultrasound machine (Philips Healthcare)•Left subclavian venous access: used for pulmonary artery catheterization◦Micropuncture kit with needle and wire (Cook Medical)◦Arrowg+ard Blue PSI 8.5-F sheath (Arrow Medical Co)◦Swan-Ganz VIP nonheparin 7.5-F (Edwards Lifesciences)•Left femoral venous access: used for temporary venous pacing and later trialysis catheter placement◦Micropuncture kit (Cook Medical)◦Pinnacle R/O II introducer sheath 6 F × 25 cm (Terumo Corp)◦5 F × 110 cm sheath (Arrow Medical Co)◦13 F × 30 cm Trialysis catheter (Bard Medical)•Right femoral arterial access (surgical cutdown):◦Pinnacle introducer sheath 6 F × 10 cm (Terumo Corp)◦Amplatz Super Stiff J tip 0.035 inch/260 cm wire (Boston Scientific)◦Used 2 Perclose devices using preclose technique: Perclose suture-mediated closure and repair (SMCR) system (Abbott)◦14-F E-sheath (Edwards Lifesciences)•Impulse AL1 6 F × 100 cm catheter (Boston Scientific)◦Inserted over standard J-guidewire◦J-wire exchanged for Glidewire straight 0.035 inch × 260 cm (Terumo Corp)◦Placed in the left ventricle•Impulse PIG 155 (angled pigtail) 6 F × 110 cm (Boston Scientific)◦Inserted over fixed core Safe-T-J curved 0.035 inch/260 cm (Cook Medical)◦Placed in the ascending aorta•Safari 2 extra small 0.035 inch × 275 cm wire (Boston Scientific)◦Inserted into the pigtail, into the left ventricle (pigtail then removed)•Commander delivery system 26 mm × 3.2 cm × 105 cm (Edwards Lifesciences)◦Delivered over Safari wire•TAVR device: 26-mm Sapien 3 Ultra Resilia (Edwards Lifesciences)TAVR = transcatheter aortic valve replacement. Transcatheter Aortic Valve-in-Valve Repair •Transthoracic echocardiography: Philips Epiq 7 (Philips Healthcare) Transthoracic echocardiography: Philips Epiq 7 (Philips Healthcare) •Chest/Abdomen/Pelvis computed tomography angiography (external imaging, unknown machine type) Chest/Abdomen/Pelvis computed tomography angiography (external imaging, unknown machine type) •Transesophageal echocardiography: Philips Epiq 7 (Philips Healthcare) Transesophageal echocardiography: Philips Epiq 7 (Philips Healthcare) •Ultrasound machine (Philips Healthcare) Ultrasound machine (Philips Healthcare) •Left subclavian venous access: used for pulmonary artery catheterization◦Micropuncture kit with needle and wire (Cook Medical)◦Arrowg+ard Blue PSI 8.5-F sheath (Arrow Medical Co)◦Swan-Ganz VIP nonheparin 7.5-F (Edwards Lifesciences) Left subclavian venous access: used for pulmonary artery catheterization◦Micropuncture kit with needle and wire (Cook Medical)◦Arrowg+ard Blue PSI 8.5-F sheath (Arrow Medical Co)◦Swan-Ganz VIP nonheparin 7.5-F (Edwards Lifesciences) ◦Micropuncture kit with needle and wire (Cook Medical) Micropuncture kit with needle and wire (Cook Medical) ◦Arrowg+ard Blue PSI 8.5-F sheath (Arrow Medical Co) Arrowg+ard Blue PSI 8.5-F sheath (Arrow Medical Co) ◦Swan-Ganz VIP nonheparin 7.5-F (Edwards Lifesciences) Swan-Ganz VIP nonheparin 7.5-F (Edwards Lifesciences) •Left femoral venous access: used for temporary venous pacing and later trialysis catheter placement◦Micropuncture kit (Cook Medical)◦Pinnacle R/O II introducer sheath 6 F × 25 cm (Terumo Corp)◦5 F × 110 cm sheath (Arrow Medical Co)◦13 F × 30 cm Trialysis catheter (Bard Medical) Left femoral venous access: used for temporary venous pacing and later trialysis catheter placement◦Micropuncture kit (Cook Medical)◦Pinnacle R/O II introducer sheath 6 F × 25 cm (Terumo Corp)◦5 F × 110 cm sheath (Arrow Medical Co)◦13 F × 30 cm Trialysis catheter (Bard Medical) ◦Micropuncture kit (Cook Medical) Micropuncture kit (Cook Medical) ◦Pinnacle R/O II introducer sheath 6 F × 25 cm (Terumo Corp) Pinnacle R/O II introducer sheath 6 F × 25 cm (Terumo Corp) ◦5 F × 110 cm sheath (Arrow Medical Co) 5 F × 110 cm sheath (Arrow Medical Co) ◦13 F × 30 cm Trialysis catheter (Bard Medical) 13 F × 30 cm Trialysis catheter (Bard Medical) •Right femoral arterial access (surgical cutdown):◦Pinnacle introducer sheath 6 F × 10 cm (Terumo Corp)◦Amplatz Super Stiff J tip 0.035 inch/260 cm wire (Boston Scientific)◦Used 2 Perclose devices using preclose technique: Perclose suture-mediated closure and repair (SMCR) system (Abbott)◦14-F E-sheath (Edwards Lifesciences) Right femoral arterial access (surgical cutdown):◦Pinnacle introducer sheath 6 F × 10 cm (Terumo Corp)◦Amplatz Super Stiff J tip 0.035 inch/260 cm wire (Boston Scientific)◦Used 2 Perclose devices using preclose technique: Perclose suture-mediated closure and repair (SMCR) system (Abbott)◦14-F E-sheath (Edwards Lifesciences) ◦Pinnacle introducer sheath 6 F × 10 cm (Terumo Corp) Pinnacle introducer sheath 6 F × 10 cm (Terumo Corp) ◦Amplatz Super Stiff J tip 0.035 inch/260 cm wire (Boston Scientific) Amplatz Super Stiff J tip 0.035 inch/260 cm wire (Boston Scientific) ◦Used 2 Perclose devices using preclose technique: Perclose suture-mediated closure and repair (SMCR) system (Abbott) Used 2 Perclose devices using preclose technique: Perclose suture-mediated closure and repair (SMCR) system (Abbott) ◦14-F E-sheath (Edwards Lifesciences) 14-F E-sheath (Edwards Lifesciences) •Impulse AL1 6 F × 100 cm catheter (Boston Scientific)◦Inserted over standard J-guidewire◦J-wire exchanged for Glidewire straight 0.035 inch × 260 cm (Terumo Corp)◦Placed in the left ventricle Impulse AL1 6 F × 100 cm catheter (Boston Scientific)◦Inserted over standard J-guidewire◦J-wire exchanged for Glidewire straight 0.035 inch × 260 cm (Terumo Corp)◦Placed in the left ventricle ◦Inserted over standard J-guidewire Inserted over standard J-guidewire ◦J-wire exchanged for Glidewire straight 0.035 inch × 260 cm (Terumo Corp) J-wire exchanged for Glidewire straight 0.035 inch × 260 cm (Terumo Corp) ◦Placed in the left ventricle Placed in the left ventricle •Impulse PIG 155 (angled pigtail) 6 F × 110 cm (Boston Scientific)◦Inserted over fixed core Safe-T-J curved 0.035 inch/260 cm (Cook Medical)◦Placed in the ascending aorta Impulse PIG 155 (angled pigtail) 6 F × 110 cm (Boston Scientific)◦Inserted over fixed core Safe-T-J curved 0.035 inch/260 cm (Cook Medical)◦Placed in the ascending aorta ◦Inserted over fixed core Safe-T-J curved 0.035 inch/260 cm (Cook Medical) Inserted over fixed core Safe-T-J curved 0.035 inch/260 cm (Cook Medical) ◦Placed in the ascending aorta Placed in the ascending aorta •Safari 2 extra small 0.035 inch × 275 cm wire (Boston Scientific)◦Inserted into the pigtail, into the left ventricle (pigtail then removed) Safari 2 extra small 0.035 inch × 275 cm wire (Boston Scientific)◦Inserted into the pigtail, into the left ventricle (pigtail then removed) ◦Inserted into the pigtail, into the left ventricle (pigtail then removed) Inserted into the pigtail, into the left ventricle (pigtail then removed) •Commander delivery system 26 mm × 3.2 cm × 105 cm (Edwards Lifesciences)◦Delivered over Safari wire Commander delivery system 26 mm × 3.2 cm × 105 cm (Edwards Lifesciences)◦Delivered over Safari wire ◦Delivered over Safari wire Delivered over Safari wire •TAVR device: 26-mm Sapien 3 Ultra Resilia (Edwards Lifesciences) TAVR device: 26-mm Sapien 3 Ultra Resilia (Edwards Lifesciences) TAVR = transcatheter aortic valve replacement. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References